Efficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year study
|
|
- Sheila Lindsey
- 5 years ago
- Views:
Transcription
1 Rheumatol Int (2006) 26: DOI /s ORIGINAL ARTICLE J. D. Ringe Æ H. Faber Æ P. Farahmand Æ A. Dorst Efficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year study Received: 14 March 2005 / Accepted: 21 March 2005 / Published online: 7 July 2005 Ó Springer-Verlag 2005 Abstract Osteoporosis is prevalent in men with an estimated one in eight men older than 50 years suffering from osteoporotic fracture, and a higher mortality rate after fracture among men compared with women. There are few approved therapies for osteoporosis in men. This observational study assesses the efficacy and safety of risedronate in the treatment of men with primary and secondary osteoporosis. A single-center, open label, randomized, prospective 1-year study was conducted in men with primary or secondary osteoporosis. Patients were randomized to risedronate (risedronate 5 mg/day plus calcium 1,000 mg/day and vitamin D 800 IU/day) or control groups (alfacalcidol 1 lg/day plus calcium 500 mg/day or vitamin D 1,000 IU/day plus calcium 800 mg/day). Bone mineral density (BMD) measurements, X-rays of the spine, a medical history and physical exam, and patient self-assessments of back pain were performed at baseline and 12 months. Blinded semi-quantitative fracture assessment was conducted by a radiologist. A total of 316 men with osteoporosis were enrolled in the trial (risedronate, n=158; control, n=158). At 1 year lumbar spine BMD increased by 4.7% in the risedronate group versus an increase of 1.0% in the control group (P<0.001). Significant increases in BMD at the total hip and femoral neck were also observed with risedronate compared with the control group. The incidence of new vertebral fracture in the risedronate group was reduced by 60% versus the control group (P=0.028). Daily treatment with risedronate for 12 months significantly increased BMD at the lumbar spine, femoral neck and total hip and significantly reduced the incidence of new vertebral fractures. This is the first prospective, randomized, controlled trial to J. D. Ringe (&) Æ H. Faber Æ P. Farahmand Æ A. Dorst Medizinische Klinik 4, Allgemeine Innere (Rheumatology/Osteology), Klinikum Leverkusen, Akademisches Lehrkrankenhaus der Universita t zu Ko ln, Leverkusen, Germany ringe@klinikum-lev.de demonstrate a significant reduction in vertebral fractures in 1 year in men with primary or secondary osteoporosis. Keywords Risedronate Æ Male Æ Osteoporosis Æ Bisphosphonates Æ Vertebral fracture Æ Non-vertebral fracture Introduction Osteoporosis is a common disease in postmenopausal women that manifests itself as fractures, most commonly at the spine, hip or wrist, and causes significant morbidity and mortality [1]. Although osteoporosis is less prevalent in men, it has been estimated that 30% of all hip fractures occur in males and that one in eight men older than 50 years will experience an osteoporotic fracture [2]. Moreover, studies have shown that the mortality rate after fracture in men is higher compared with that in women [3, 4]. There are few approved therapies for osteoporosis in men, and the disease remains largely under-diagnosed and under-treated [5, 6]. Androgen replacement therapy is effective in hypogonadal men [7], but they represent only a small proportion of men with osteoporosis. More recently, the bisphosphonate alendronate was shown to be effective for treatment of male osteoporosis [8 10]; and both alendronate and risedronate have been approved for treatment of glucorticoid-induced osteoporosis (GIO) in men in a variety of geographies [11]. Risedronate is a potent bisphosphonate that inhibits osteoclast activity and has been demonstrated to reduce both clinical vertebral and nonvertebral fractures in postmenopausal women within 6 months of treatment [12, 13] and to reduce hip fractures over a 3-year treatment period [14]. In men, risedronate has been shown to reduce vertebral fractures in patients with glucocorticoid-induced osteoporosis within 1 year [15, 16]. The aim of the present trial was to investigate the 1 year
2 428 therapeutic efficacy of risedronate in a pure male population with primary and secondary osteoporosis. Methods Study subjects This was a single-center, open label, randomized, prospective 1-year study, which enrolled men with primary or secondary osteoporosis. Osteoporosis was defined as a baseline lumbar spine bone mineral density (BMD) T-score of )2.5 SD and a baseline femoral neck BMD T-score of )2.0 relative to a healthy young adult male reference population. Men with or without pre-existing prevalent vertebral fractures were included in the study. The distinction primary or secondary osteoporosis was based on a thorough history of possible risk factors, medications or underlying diseases and complementary laboratory examinations. Patients with known hypersensitivity to bisphosphonates, severe impairment of renal function, hypocalcaemia and a history of bisphosphonate or fluoride pretreatment within the last 12 months were excluded from the study. Study design Eligible patients were randomized to risedronate or control groups, stratified by the presence of prevalent vertebral fractures at baseline. All patients in the risedronate treatment arm received risedronate (5 mg daily), elementary calcium (1,000 mg daily) and vitamin D (800 IU daily). Patients in the control group received one of two treatments dependent upon the presence of prevalent vertebral fractures: patients with prevalent vertebral fractures received alfacalcidol (1 lg daily) and calcium (500 mg daily); patients with no previous vertebral fractures received plain vitamin D (1,000 IU daily) and calcium (800 mg daily). Patient visits were performed at baseline and 12 months. Outcome measurements BMD was measured at baseline and observer blind at 12 months at the lumbar spine, femoral neck and hip by dual energy X-ray absorptiometry using the DEXA- Expert technique (Lunar Corp., Madison, WI, USA). Instrument and operator quality control measures were conducted and analyzed throughout the study. T-scores at baseline for the lumbar spine and femoral neck were calculated from a young male database provided by the manufacturer. Radiographic X-rays of the spine were obtained at baseline and 12 months. Assessment of vertebral fracture was performed using the semi-quantitative technique by a radiologist who was blinded to treatment allocation. Definitive fractures were determined by visual inspection. For equivocal vertebral fractures, vertebral heights were measured (anterior, median, posterior) and incident vertebral fractures were defined as a decrease in any vertebral height of at least 20%. A medical history and physical examination, including single height measurements, were obtained at all visits. Back pain was scored by patients at baseline and 12 months using a four-point self-assessment scale: 0=none, 1=mild, 2=moderate, 3=severe. Efficacy endpoints The primary efficacy endpoint was change in BMD at the lumbar spine. Secondary endpoints included assessment of the incidence of new vertebral fractures; change in BMD at the femoral neck and total hip; change in body height; course of back pain; and the incidence of non-vertebral fractures. Statistical analysis All analyses were performed within the intent-to-treat population, which included all patients who received at least one dose of study medication. Changes in BMD after 12 months were compared using analysis of covariance with the baseline BMD value as covariate. The Wilcoxon Mann Whitney U-test (continuous data) or Fisher s exact test (categorical data) was used to compare differences between treatment groups. All comparisons were two-sided and a P<0.05 was considered statistically significant. Results Patients and baseline characteristics From a screened population of 580 men sent to our outpatient department for diagnosis and/or treatment of osteoporosis a total of 316 men fulfilling the inclusion criteria and given the diagnosis of primary or secondary osteoporosis; were enrolled into the trial (risedronate, n=158; control, n=158). The number of patients with at least one prevalent vertebral fracture at baseline was similar in both treatment groups. A total of 84 (53.2%) and 81 (51.3%) patients had at least one prevalent fracture in the risedronate and control groups, respectively. Patient disposition is shown in Fig. 1. The baseline characteristics were similar and are summarized in Table 1. The mean lumbar spine and femoral neck BMD were approximately 3.3 and 2.5 SD, respectively, below the normal reference young adult mean. In the risedronate treatment group, a total of 94 patients had primary osteoporosis and 64 patients had secondary osteoporosis. In the control group a total of 92 and 66 patients had
3 429 Fig. 1 Patient disposition Table 1 Baseline patient characteristics primary and secondary osteoporosis, respectively. All 316 patients were re-examined at month 12. BMD changes Risedronate (n=158) Control a (n=158) Age (years) 55.8 (10.5) 58.0 (10.3) Weight (kg) 76.2 (13.5) 73.1 (9.6) Height (cm) (7.0) (6.2) Lumbar spine BMD T-score )3.34 )3.29 Femoral neck BMD T-score )2.45 )2.59 Total hip BMD T-score )2.63 )2.65 Prevalent vertebral fractures (%) Data are given as mean (SD) unless otherwise specified a Received alfacalcidol/vitamin D and calcium The findings of the primary efficacy endpoint showed that treatment with risedronate resulted in a significant increase in lumbar spine BMD compared with the control group. At 1 year, there was an average 4.7% increase in the lumbar spine BMD in patients treated with risedronate compared with an increase of 1.0% in the control group (P<0.0001). Similarly, at the other BMD measurement sites total hip and femoral neck risedronate treatment produced a significant increase in BMD compared with the control group. The mean BMD percent changes after 12 months in patients treated with risedronate were +2.7% at the total hip and +1.8% at the femoral neck compared with +0.4% and +0.2% respectively, in the control group (P<0.0001) (Fig. 2). Fig. 2 Percent change in BMD from baseline to 12 months in men with osteoporosis in the risedronate and control groups Over 1 year, the incidence of new vertebral fractures in the risedronate group was reduced by 60% versus the control group (P=0.028) (Fig. 3). Over 1 year, 8 patients suffered new vertebral fractures (5.1%) in the risedronate treated group, compared with 20 patients with new vertebral fractures (12.7%) in the control group. Assessment of the incidence of nonvertebral fractures showed that there was a 42% reduction in the risedronate-treated group compared with control, although this difference did not reach statistical significance (P=0.227). Over 1 year, nonvertebral fractures occurred in 10 patients (6.3%) in the risedronate-treated group compared with 17 patients (10.8%) in the control group. Body height After 1 year of treatment, the average rate of height loss was significantly lower in the risedronate group compared with the control group (1.1 mm in the risedronate group versus )4.6 mm in the control group, P<0.001). Back pain Significant improvements in mean back pain score were observed for both treatment groups compared with baseline at 1 year (P<0.0001). Comparison of the mean Fracture incidence Fig. 3 Incidence of new vertebral fractures in patients treated with control or risedronate 5 mg
4 430 back pain scores between treatment groups showed that the improvement in back pain in patients treated with risedronate was significantly greater compared with the control group (P<0.0001). In patients treated with risedronate, 32% of the patients reported no back pain, and 45%, 20%, and 3% of patients reported mild, moderate and severe back pain, respectively. In contrast, in the control group, 7% had no back pain and 44%, 36% and 13% of patients had mild, moderate and severe back pain, respectively. Safety assessments In all patients laboratory examinations of blood (blood count, ygt, alk.phosph., LDH, Na, K, Ca, Pi, Fe, creat, uric acid, total protein, protein electropheresis) and 24- h-urine (creat., Ca, Pi) were performed at onset and after 12 months. There was no difference in number and quality of adverse events between the two groups. We did not observe any severe adverse event or withdrawal due to the antiosteoporotic medication. Discussion Despite the large number of men affected, osteoporosis in this population remains largely under-diagnosed and under-treated. We report here the first study to demonstrate early treatment effects in men with established osteoporosis. Daily treatment with risedronate 5 mg resulted in significant BMD increases of approximately 5% at the lumbar spine, 2% at the femoral neck and 3% at the hip in men at 1 year. Assessment of fracture showed a 60% reduction in the number of patients with new vertebral fractures compared with control patients (P=0.028), within 1 year of treatment. The current study also demonstrated significant reductions in height loss and back pain compared with control (P<0.001). Several studies have shown that there is a high risk for future fracture in patients with pre-existing or new incident vertebral fractures [17 19], exemplifying the need for rapid and effective fracture protection to prevent the fracture cascade from taking hold. The rapid reduction in the incidence of vertebral fractures observed in this study is consistent with the results of risedronate treatment for CIO in men reported by Reid et al. [15, 16], in which risedronate treatment resulted in an 82% reduction in the incidence of vertebral fractures at 1 year. Studies of risedronate treatment in postmenopausal women with osteoporosis have also shown reductions in the incidence of radiographically defined fracture by 65% at 1 year [20, 21]. In addition, a recent retrospective analysis by Roux et al. [12] examining the time course of fracture risk reduction in the risedronate VERT studies (MN and NA) showed that treatment with risedronate significantly reduced the incidence of clinical vertebral fractures within 6 months of treatment (P<0.05). Two studies have shown that alendronate increases BMD in men with osteoporosis [8, 10]; one of these studies showed a significant reduction of vertebral fractures after 2 years of treatment using a quantitative morphometric method, although these findings did not reach significance when a semiquantitative method was used [10]. At 1 year, the incidence of nonvertebral fractures in the risedronate group was reduced by 42% compared with control, although this did not reach statistical significance. Recently, a pooled analysis of four large randomized, double-blind, placebo-controlled studies in postmenopausal women [13] showed that risedronate significantly reduced the incidence of nonvertebral fractures after 1 year by 74% compared with control. Limitations of the study include the open label design, which could have introduced potential bias. To allow objective evaluation, especially of patient radiographs, the radiologist was not informed about the patient s treatment allocation. In addition, measurements were made only at baseline and at 12 months, limiting assessment at earlier time points. In summary, this is the first prospective, randomized, controlled study to demonstrate a rapid reduction in vertebral fractures in men with primary and secondary osteoporosis following treatment with the bisphosphonate, risedronate. References 1. Barrett-Connor E (1995) The economic and human costs of osteoporotic fracture. Am J Med 98(2A):3S 8S 2. Campion JM, Maricic MJ (2003) Osteoporosis in men. Am Fam Physician 67(7): Center JR et al (1999) Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 353(9156): Olszynski WP et al (2004) Osteoporosis in men: epidemiology, diagnosis, prevention, and treatment. Clin Ther 26(1): Kiebzak GM et al (2002) Undertreatment of osteoporosis in men with hip fracture. Arch Intern Med 162(19): Nguyen TV, Center JR, Eisman JA (2004) Osteoporosis: underrated, underdiagnosed and undertreated. Med J Aust 180(5 Suppl):S18 S22 7. Snyder PJ et al (2000) Effects of testosterone replacement in hypogonadal men. J Clin Endocrinol Metab 85(8): Orwoll E et al (2000) Alendronate for the treatment of osteoporosis in men. N Engl J Med 343(9): Ringe JD, Orwoll E, Daifotis A, Lombardi A (2002) Treatment of male osteoporosis: recent advances with alendronate. Osteoporos Int 13: Ringe JD, Dorst A, Faber H, Ibach K (2004) Alendonate treatment of established primary osteoporosis in men: 3-year results of a prospective, comparative, two-arm study. Rheumatol Int 24: Physicians desk reference: PDR (2003) 57th edn. Thomson PDR, Montvale, p Roux C et al (2004) Efficacy of risedronate on clinical vertebral fractures within six months. Curr Med Res Opin 20(4): Harrington T et al (2004) Risedronate rapidly reduces the risk for non-vertebral fractures in women with postmenopausal osteoporosis. Calcif Tissue Int 74: McClung MR et al (2001) Effect of risedronate on the risk of hip fracture in elderly women Hip Intervention Program Study Group. N Engl J Med 344(5):
5 Reid DM et al (2001) Risedronate increases bone density and reduces vertebral fracture risk within one year in men on corticosteroid therapy. Calcif Tissue Int 69(4): Lindsay R et al (2001) Risk of new vertebral fracture in the year following a fracture. JAMA 285(3): Ringe JD (2000) Osteoporosis in men. In: Hosking D, Ringe J (eds) Treatment of metabolic bone disease. Management strategy and drug therapy. Martin Dunitz, London 18. Hasserius R et al (2003) Prevalent vertebral deformities predict increased mortality and increased fracture rate in both men and women: a 10-year population-based study of 598 individuals from the Swedish cohort in the European Vertebral Osteoporosis Study. Osteoporos Int 4(1): Ross PD et al (1991) Pre-existing fractures and bone mass predict vertebral fracture incidence in women. Ann Intern Med 114(11): Harris ST et al (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 282(14): Reginster J et al (2000) Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 11(1):83 91
Fragile Bones and how to recognise them. Rod Hughes Consultant physician and rheumatologist St Peter s hospital Chertsey
Fragile Bones and how to recognise them Rod Hughes Consultant physician and rheumatologist St Peter s hospital Chertsey Osteoporosis Osteoporosis is a skeletal disorder characterised by compromised bone
More informationOsteoporosis in Men. Until recently, the diagnosis of osteoporosis. A New Type of Patient. Al s case. How is the diagnosis made?
A New Type of Patient Rafat Faraawi, MD, FRCP(C), FACP Until recently, the diagnosis of osteoporosis in men was uncommon and, when present, it was typically described as a consequence of secondary causes.
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 21 July 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 21 July 2010 ACTONEL 5 mg, film-coated tablet B/14 (CIP code: 354 362-3) ACTONEL 30 mg, film-coated tablet B/28 (CIP
More informationModule 5 - Speaking of Bones Osteoporosis For Health Professionals: Fracture Risk Assessment. William D. Leslie, MD MSc FRCPC
Module 5 - Speaking of Bones Osteoporosis For Health Professionals: Fracture Risk Assessment William D. Leslie, MD MSc FRCPC Case #1 Age 53: 3 years post-menopause Has always enjoyed excellent health with
More informationdenosumab (Prolia ) Policy # Original Effective Date: 07/21/2011 Current Effective Date: 04/19/2017
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationBased on review of available data, the Company may consider the use of denosumab (Prolia) for the
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationO. Bruyère M. Fossi B. Zegels L. Leonori M. Hiligsmann A. Neuprez J.-Y. Reginster
DOI 10.1007/s00296-012-2460-y ORIGINAL ARTICLE Comparison of the proportion of patients potentially treated with an anti-osteoporotic drug using the current criteria of the Belgian national social security
More informationPrevalence of vertebral fractures on chest radiographs of elderly African American and Caucasian women
Osteoporos Int (2011) 22:2365 2371 DOI 10.1007/s00198-010-1452-6 ORIGINAL ARTICLE Prevalence of vertebral fractures on chest radiographs of elderly African American and Caucasian women D. Lansdown & B.
More informationnogg Guideline for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK
nogg NATIONAL OSTEOPOROSIS GUIDELINE GROUP Guideline for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK Produced by J Compston, A Cooper,
More informationName of Policy: Zoledronic Acid (Reclast ) Injection
Name of Policy: Zoledronic Acid (Reclast ) Injection Policy #: 355 Latest Review Date: May 2011 Category: Pharmacy Policy Grade: Active Policy but no longer scheduled for regular literature reviews and
More informationOSTEOPOROSIS MANAGEMENT AND INVESTIGATION. David A. Hanley, MD, FRCPC
OSTEOPOROSIS MANAGEMENT AND INVESTIGATION David A. Hanley, MD, FRCPC There is a huge care gap in the management of osteoporosis in this country. As yet unpublished findings from the Canadian Multicentre
More informationComparison of the efficacy of three once-weekly bisphosphonates on bone mineral density gains in Korean women
Original Article Obstet Gynecol Sci 2013;56(3):176-181 http://dx.doi.org/10.5468/ogs.2013.56.3.176 pissn 2287-8572 eissn 2287-8580 Comparison of the efficacy of three once-weekly bisphosphonates on bone
More informationBAD TO THE BONE. Peter Jones, Rheumatologist QE Health, Rotorua. GP CME Conference Rotorua, June 2008
BAD TO THE BONE Peter Jones, Rheumatologist QE Health, Rotorua GP CME Conference Rotorua, June 2008 Agenda Osteoporosis in Men Vitamin D and Calcium Long-term treatment with Bisphosphonates Pathophysiology
More informationAn audit of osteoporotic patients in an Australian general practice
professional Darren Parker An audit of osteoporotic patients in an Australian general practice Background Osteoporosis is a major contributor to morbidity and mortality in Australia, and is predicted to
More informationDownload slides:
Download slides: https://www.tinyurl.com/m67zcnn https://tinyurl.com/kazchbn OSTEOPOROSIS REVIEW AND UPDATE Boca Raton Regional Hospital Internal Medicine Conference 2017 Benjamin Wang, M.D., FRCPC Division
More informationThis house believes that HRT should be the first-line prevention for postmenopausal osteoporosis: the case against
This house believes that HRT should be the first-line prevention for postmenopausal osteoporosis: the case against Juliet Compston Professor of Bone Medicine University of Cambridge School of Clinical
More information8/6/2018. Glucocorticoid induced osteoporosis: overlooked and undertreated? Disclosure. Objectives. Overview
Disclosure Glucocorticoid induced osteoporosis: overlooked and undertreated? I have no financial disclosure relevant to this presentation Tasma Harindhanavudhi, MD Division of Diabetes and Endocrinology
More informationPresenter: 翁家嫻 Venue date:
FOR THE TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN AT INCREASED RISK OF FRACTURES 1 Presenter: 翁家嫻 Venue date: 2018.03.13 PMO: postmenopausal osteoporosis. 1. Prolia (denosumab), Summary of Product
More informationCASE 1 WHY IS IT IMPORTANT TO TREAT? FACTS CONCERNS
4:30-5:15pm Ask the Expert: Osteoporosis SPEAKERS Silvina Levis, MD OSTEOPOROSIS - FACTS 1:3 older women and 1:5 older men will have a fragility fracture after age 50 After 3 years of treatment, depending
More informationSubmission to the National Institute for Clinical Excellence on
Submission to the National Institute for Clinical Excellence on Strontium ranelate for the prevention of osteoporotic fractures in postmenopausal women with osteoporosis by The Society for Endocrinology
More informationUsing the FRAX Tool. Osteoporosis Definition
How long will your bones remain standing? Using the FRAX Tool Gary Salzman M.D. Director Banner Good Samaritan/ Hayden VAMC Internal Medicine Geriatric Fellowship Program Phoenix, Arizona Using the FRAX
More informationBreast Cancer and Bone Loss. One in seven women will develop breast cancer during a lifetime
Breast Cancer and Bone Loss One in seven women will develop breast cancer during a lifetime Causes of Bone Loss in Breast Cancer Patients Aromatase inhibitors Bil Oophorectomy Hypogonadism Steroids Chemotherapy
More informationB3D-MC-GHCY Clinical Study Report Synopsis Page 1Page GHCY Synopsis LY
B3DMCGHCY Clinical Study Report Page 1Page 1 2. GHCY B3DMCGHCY Clinical ClinicalStudy StudyReport Report Page 2Page 2 Clinical Study Report : Study B3DMCGHCY Title of Study: The Effect of Teriparatide
More informationDr Tuan V NGUYEN. Mapping Translational Research into Individualised Prognosis of Fracture Risk
Dr Tuan V NGUYEN Bone and Mineral Research Program, Garvan Institute of Medical Research, Sydney NSW Mapping Translational Research into Individualised Prognosis of Fracture Risk From the age of 60, one
More informationVol. 19, Bulletin No. 108 August-September 2012 Also in the Bulletin: Denosumab 120mg for Bone Metastases
ה מ ר א פ הביטאון לענייני תרופות ISRAEL DRUG BULLETIN 19 years of unbiased and independent drug information P H A R x M A Vol. 19, Bulletin No. 108 August-September 2012 Also in the Bulletin: Denosumab
More informationMale osteoporosis: clinical approach and management in family practice
Singapore Med J 2014; 55(7): 353-357 doi: 10.11622/smedj.2014085 CMEArticle Male osteoporosis: clinical approach and management in family practice Lay Hoon Goh 1,2, MMed, FCFP, Choon How How 1, MMed, FCFP,
More informationOsteoporosis challenges
Osteoporosis challenges Osteoporosis challenges Who should have a fracture risk assessment? Who to treat? Drugs, holidays and unusual adverse effects Fracture liaison service? The size of the problem 1
More informationCurrent Issues in Osteoporosis
Current Issues in Osteoporosis California AACE 18TH Annual Meeting & Symposium Marina del Rey, CA September 15, 2018 Michael R. McClung, MD, FACP,FACE Director, Oregon Osteoporosis Center Portland, Oregon,
More informationThe Significance of Vertebral Fractures
Special Report The Significance of Vertebral Fractures Both the prevalence and the clinical significance of vertebral fractures has been greatly underestimated by physicians. Vertebral fractures are much
More informationProduct: Denosumab (AMG 162) Clinical Study Report: month Primary Analysis Date: 21 November 2016 Page 1
Date: 21 November 2016 Page 1 2. SYNOPSIS Name of Sponsor: Amgen Inc., Thousand Oaks, CA, USA Name of Finished Product: Prolia Name of Active Ingredient: denosumab Title of Study: Randomized, Double-blind,
More informationSponsor / Company: sanofi-aventis and Proctor & Gamble Drug substance(s): Risedronate (HMR4003)
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: sanofi-aventis and
More informationOSTEOPOROSIS: PREVENTION AND MANAGEMENT
OSTEOPOROSIS: OVERVIEW OSTEOPOROSIS: PREVENTION AND MANAGEMENT Judith Walsh, MD, MPH Departments of Medicine and Epidemiology and Biostatistics UCSF Definitions Key Risk factors Screening and Monitoring
More informationSkeletal Manifestations
Skeletal Manifestations of Metabolic Bone Disease Mishaela R. Rubin, MD February 21, 2008 The Three Ages of Women Gustav Klimt 1905 1 Lecture Outline Osteoporosis epidemiology diagnosis secondary causes
More informationDiagnostische Präzision von DXL im Vergleich zu DXA bei pmp Frauen mit Frakturen
Diagnostische Präzision von DXL im Vergleich zu DXA bei pmp Frauen mit Frakturen Christian Muschitz II. Medizinische Abteilung mit Rheumatologie, Osteologie & Gastroenterologie Akademisches Lehrkrankenhaus
More informationPharmacy Management Drug Policy
SUBJECT: - Forteo (teriparatide), Prolia (denosumab), Tymlos (abaloparatide) POLICY NUMBER: Pharmacy-35 EFFECTIVE DATE: 9/07 LAST REVIEW DATE: 9/29/2017 If the member s subscriber contract excludes coverage
More informationHorizon Scanning Technology Briefing. Zoledronic Acid (Aclasta) once yearly treatment for postmenopausal. National Horizon Scanning Centre
Horizon Scanning Technology Briefing National Horizon Scanning Centre Zoledronic Acid (Aclasta) once yearly treatment for postmenopausal osteoporosis December 2006 This technology summary is based on information
More informationMen and Osteoporosis So you think that it can t happen to you
Men and Osteoporosis So you think that it can t happen to you Jonathan D. Adachi MD, FRCPC Alliance for Better Bone Health Chair in Rheumatology Professor, Department of Medicine Michael G. DeGroote School
More informationEndocrine Unit and Chair of Endocrinology Director Prof. Manuela Simoni. Hot topics in osteoporosis. How long to treat
Endocrine Unit and Chair of Endocrinology Director Prof. Manuela Simoni Hot topics in osteoporosis How long to treat Dott. Bruno Madeo bruno.madeo@unimore.it www.endocrinologia.unimore.it/on-line/home.html
More informationForteo (teriparatide) Prior Authorization Program Summary
Forteo (teriparatide) Prior Authorization Program Summary FDA APPROVED INDICATIONS DOSAGE 1 FDA Indication 1 : Forteo (teriparatide) is indicated for: the treatment of postmenopausal women with osteoporosis
More informationJuly 2012 CME (35 minutes) 7/12/2016
Financial Disclosures Epidemiology and Consequences of Fractures Advisory Board: Amgen Janssen Pharmaceuticals Inc. Ann V. Schwartz, PhD Department of Epidemiology and Biostatistics UCSF Outline Osteoporotic
More informationGuideline for the investigation and management of osteoporosis. for hospitals and General Practice
Guideline for the investigation and management of osteoporosis for hospitals and General Practice Background Low bone density is an important risk factor for fracture. The aim of assessing bone density
More informationName of Policy: Boniva (Ibandronate Sodium) Infusion
Name of Policy: Boniva (Ibandronate Sodium) Infusion Policy #: 266 Latest Review Date: April 2010 Category: Pharmacology Policy Grade: Active Policy but no longer scheduled for regular literature reviews
More information2017 Santa Fe Bone Symposium McClung
217 Santa Fe Bone Symposium Insights into the Use of Anti-remodeling and Anabolic Agents for Osteoporosis Developing a Long-term Management Plan Michael R., MD, FACP Oregon Osteoporosis Center Portland,
More informationAssessment and Treatment of Osteoporosis Professor T.Masud
Assessment and Treatment of Osteoporosis Professor T.Masud Nottingham University Hospitals NHS Trust University of Nottingham University of Derby University of Southern Denmark What is Osteoporosis? Osteoporosis
More informationDifferentiating Pharmacological Therapies for Osteoporosis
Differentiating Pharmacological Therapies for Osteoporosis Socrates E Papapoulos Department of Endocrinology & Metabolic Diseases Leiden University Medical Center The Netherlands Competing interests: consulting/speaking
More informationPharmacy Management Drug Policy
Clinical criteria used to make utilization review decisions are based on credible scientific evidence published in peer reviewed medical literature generally recognized by the medical community. Guidelines
More informationOsteoporosis/Fracture Prevention
Osteoporosis/Fracture Prevention NATIONAL GUIDELINE SUMMARY This guideline was developed using an evidence-based methodology by the KP National Osteoporosis/Fracture Prevention Guideline Development Team
More informationOSTEOPOROSIS IN MEN. Nelson B. Watts, MD OSTEOPOROSIS AND BONE HEALTH SERVICES CINCINNATI, OHIO
OSTEOPOROSIS IN MEN Nelson B. Watts, MD OSTEOPOROSIS AND BONE HEALTH SERVICES CINCINNATI, OHIO DISCLOSURES Speakers Bureau: Amgen, Radius Consultant: Abbvie, Amgen, Janssen, Radius, Sanofi Watts NB et
More informationCalcium and Vitamin D Supplementation is an Ineffective Strategy for the Prevention of Fractures in Older People
Calcium and Vitamin D Supplementation is an Ineffective Strategy for the Prevention of Fractures in Older People For the Motion: Professor Roger Francis, Institute for Ageing and Health, Newcastle University,
More informationSCIENTIFIC DISCUSSION. London, 24 May 2007 Product name: FORSTEO Procedure No: EMEA/H/C/000425/II/0011
SCIENTIFIC DISCUSSION London, 24 May 2007 Product name: FORSTEO Procedure No: EMEA/H/C/000425/II/0011 TABLE OF CONTENTS I. INTRODUCTION... 3 II. CLINICAL ASPECTS... 4 2.1 Clinical pharmacology... 4 2.2
More informationAre glucocorticoid-induced osteoporosis recommendations sufficient to determine antiosteoporotic treatment for patients with rheumatoid arthritis?
ORIGINAL ARTICLE Korean J Intern Med 2014;29:509-515 Are glucocorticoid-induced osteoporosis recommendations sufficient to determine antiosteoporotic treatment for patients with rheumatoid arthritis? Joo-Hyun
More informationCalcium, Vitamin D and Bisphosphonates: Disclosures. Benefits, Risks and Drug Holiday. Calcium YES or NO? Calcium Bad News!!
Calcium, Vitamin D and Bisphosphonates: Benefits, Risks and Drug Holiday Disclosures I am disclosing financial relationships as follows: Global Advisory Boards: Amgen, Lilly, Merck, Novartis Research grants:
More informationOral Alendronate Vs. Three-Monthly Iv Ibandronate In The Treatment Of Postmenopausal Osteoporosis
Oral Alendronate Vs. Three-Monthly Iv Ibandronate In The Treatment Of Postmenopausal Osteoporosis Miriam Silverberg A. Study Purpose and Rationale More than 70% of fractures in people after the age of
More informationJ. D. Ringe, A. Dorst, H. Faber, K. Ibach and J. Preuss
Rheumatology 2003;42:743 749 doi:10.1093/rheumatology/keg205, available online at www.rheumatology.oupjournals.org Advance Access publication 16 April 2003 Three-monthly ibandronate bolus injection offers
More informationAdvanced medicine conference. Monday 20 Tuesday 21 June 2016
Advanced medicine conference Monday 20 Tuesday 21 June 2016 Osteoporosis: recent advances in risk assessment and management Juliet Compston Emeritus Professor of Bone Medicine Cambridge Biomedical Campus
More informationTalking to patients with osteoporosis about initiating therapy
Talking to patients with osteoporosis about initiating therapy Deborah Sellmeyer, MD Director, Johns Hopkins Metabolic Bone Center Dept of Medicine, Division of Endocrinology Disclosure DSMB member for
More informationOsteoporosis: Not Just for Women Anymore. Osteoporosis is characterized by low bone. By Lisanne G. Laurier, MD, PhD, FRCPC.
Focus on CME at the University of Western Ontario Osteoporosis: Not Just for Women Anymore By Lisanne G. Laurier, MD, PhD, FRCPC Osteoporosis is characterized by low bone mass and microarchitectural deterioration
More informationInterpreting DEXA Scan and. the New Fracture Risk. Assessment. Algorithm
Interpreting DEXA Scan and the New Fracture Risk Assessment Algorithm Prof. Samir Elbadawy *Osteoporosis affect 30%-40% of women in western countries and almost 15% of men after the age of 50 years. Osteoporosis
More informationParathyroid Hormone Analog for Osteoporosis Prior Authorization with Quantity Limit Criteria Program Summary
Parathyroid Hormone Analog for Osteoporosis Prior Authorization with Quantity Limit Criteria Program Summary This prior authorization program applies to Commercial, NetResults A series, NetResults F series
More informationControversies in Osteoporosis Management
Controversies in Osteoporosis Management 2018 Northwest Rheumatism Society Meeting Portland, OR April 28, 2018 Michael R. McClung, MD, FACP Director, Oregon Osteoporosis Center Portland, Oregon, USA Institute
More informationHorizon Scanning Centre March Denosumab for glucocorticoidinduced SUMMARY NIHR HSC ID: 6329
Horizon Scanning Centre March 2014 Denosumab for glucocorticoidinduced osteoporosis SUMMARY NIHR HSC ID: 6329 This briefing is based on information available at the time of research and a limited literature
More informationOsteoporosis update. Dr. Claire Vandevelde Consultant Rheumatologist, LTHT
Osteoporosis update Dr. Claire Vandevelde Consultant Rheumatologist, LTHT Outline Background BMD Tools for assessing fracture risk Case study Denosumab Treatment breaks BMD BMD predicts fracture risk but
More informationBuilding Bone Density-Research Issues
Building Bone Density-Research Issues Helping to Regain Bone Density QUESTION 1 What are the symptoms of Osteoporosis? Who is at risk? Symptoms Bone Fractures Osteoporosis 1,500,000 fractures a year Kyphosis
More informationMisuse of Bisphosphonates. Dr Rukhsana Parvin Associate Professor Department of Medicine Enam Medical College & Hospital
Misuse of Bisphosphonates Dr Rukhsana Parvin Associate Professor Department of Medicine Enam Medical College & Hospital Introduction Bisphosphonates are chemically stable analogues of pyrophosphate compounds.
More informationEffective Health Care
Number 12 Effective Health Care Comparative Effectiveness of Treatments To Prevent Fractures in Men and Women With Low Bone Density or Osteoporosis Executive Summary Background Osteoporosis is a systemic
More informationOsteoporosis is a disease that is
Pharmacologic Prevention of Osteoporotic Fractures THOMAS M. ZIZIC, M.D., Johns Hopkins University School of Medicine, Baltimore, Maryland Osteoporosis is characterized by low bone mineral density and
More informationNew 2010 Osteoporosis Guidelines: What you and your health provider need to know QUESTIONS&ANSWERS
New 2010 Osteoporosis Guidelines: What you and your health provider need to know QUESTIONS&ANSWERS Wednesday, December 1, 2010 1:00 p.m. to 2:00 p.m. ET 1. I m 55 years old. I ve been taking Fosavance
More informationDEVELOPMENT OF A RISK SCORING SYSTEM TO PREDICT A RISK OF OSTEOPOROTIC VERTEBRAL FRACTURES IN POSTMENOPAUSAL WOMEN
October 2-4, Liverpool, UK EURO SPINE 2013 DEVELOPMENT OF A RISK SCORING SYSTEM TO PREDICT A RISK OF OSTEOPOROTIC VERTEBRAL FRACTURES IN POSTMENOPAUSAL WOMEN D. Colangelo, L. A. Nasto, M. Mormando, E.
More informationPharmacy Management Drug Policy
SUBJECT: - Forteo (teriparatide), Prolia (denosumab), Tymlos (abaloparatide), Boniva injection (Ibandronate) POLICY NUMBER: Pharmacy-35 EFFECTIVE DATE: 9/07 LAST REVIEW DATE: 10/15/2018 If the member s
More informationWith older women in the United States about 4 times
Bryan Farford, DO; Jonathan Balog, DO; Kensler Dawson Jackson, MD; Daniel Montero, MD Department of Family Medicine (Drs. Farford, Balog, and Jackson); Department of Orthopedic Surgery (Dr. Montero), Mayo
More informationOsteoporosis as a Focus for Practice Improvement
Osteoporosis as a Focus for Practice Improvement Karen E. Hansen, M.D. Assistant Professor of Medicine Rheumatology and Endocrine Sections University of Wisconsin Madison, WI Postmenopausal Osteoporosis
More informationOsteoporosis. Overview
v2 Osteoporosis Overview Osteoporosis is defined as compromised bone strength that increases risk of fracture (NIH Consensus Conference, 2000). Bone strength is characterized by bone mineral density (BMD)
More informationOsteoporosis: A Tale of 3 Task Forces!
Osteoporosis: A Tale of 3 Task Forces! Robert A. Adler, MD McGuire Veterans Affairs Medical Center Virginia Commonwealth University Richmond, Virginia, USA Disclosures The opinions are those of the speaker
More informationBad to the bones: treatments for breast and prostate cancer
12 th Annual Osteoporosis: New Insights in Research, Diagnosis, and Clinical Care 23 rd July 2015 Bad to the bones: treatments for breast and prostate cancer Richard Eastell, MD FRCP (Lond, Edin, Ireland)
More informationOsteoporosis Clinical Guideline. Rheumatology January 2017
Osteoporosis Clinical Guideline Rheumatology January 2017 Introduction Osteoporosis is a condition of low bone mass leading to an increased risk of low trauma fractures. The prevalence of osteoporosis
More informationNAMS Practice Pearl. Use of Drug Holidays in Women Taking Bisphosphonates. Released April 1, 2013
NAMS Practice Pearl Use of Drug Holidays in Women Taking Bisphosphonates Released April 1, 2013 Dima L. Diab, MD 1, and Nelson B. Watts, MD 2 ( 1 Cincinnati VA Medical Center, Cincinnati, OH, 2 Mercy Health
More informationDATE: 02 August 2011 CONTEXT AND POLICY ISSUES:
TITLE: Bisphosphonates for the Prevention of Osteoporosis in Patients Treated with Systematic Corticosteroids: A Review of the Clinical Evidence and Guidelines DATE: 02 August 2011 CONTEXT AND POLICY ISSUES:
More informationClinician s Guide to Prevention and Treatment of Osteoporosis
Clinician s Guide to Prevention and Treatment of Osteoporosis Published: 15 August 2014 committee of the National Osteoporosis Foundation (NOF) Tipawan khiemsontia,md outline Basic pathophysiology screening
More informationAn Update on Osteoporosis Treatments
An Update on Osteoporosis Treatments Dr Mike Stone University Hospital Llandough Treatments for osteoporosis Calcium and vitamin D HRT Raloxifene Etidronate Alendronate Risedronate Ibandronate (oral and
More informationCurrent and Emerging Strategies for Osteoporosis
Current and Emerging Strategies for Osteoporosis I have nothing to disclose. Anne Schafer, MD Assistant Professor of Medicine Division of Endocrinology & Metabolism December 12, 2014 Outline Osteoporosis
More informationDiagnosis and management of osteoporosis
Diagnosis and management of osteoporosis Ralston SH, Fraser J. Diagnosis and management of osteoporosis. Practitioner 2015;259 (1788):15-19 Professor Stuart H Ralston MD FRCP Professor of Rheumatology,
More informationCoordinator of Post Professional Programs Texas Woman's University 1
OSTEOPOROSIS Update 2007-2008 April 26, 2008 How much of our BMD is under our control (vs. genetics)? 1 2 Genetic effects on bone loss: longitudinal twin study (Makovey, 2007) Peak BMD is under genetic
More informationEpidemiology and Consequences of Fractures
Epidemiology and Consequences of Fractures Ann V. Schwartz, PhD Department of Epidemiology and Biostatistics UCSF Financial Disclosures Advisory Board: Amgen Research Support: Hologic 24July12 1 Outline
More information11/4/2018. Osteoporosis Update. ACP Oregon Chapter November 9 th, 2018 Sarah Hopkins Providence Medical Group Endocrinology East. No disclosures.
Osteoporosis Update ACP Oregon Chapter November 9 th, 2018 Sarah Hopkins Providence Medical Group Endocrinology East No disclosures. 1 Goals Review screening recommendations and workup of secondary causes
More informationIt is estimated that more than 2
Vonda J. Wright, MD Abstract Osteoporosis is a significant threat to aging bone in men. Thirty percent of hip fractures occur in men; during initial hospitalization and the first year after fracture, the
More informationInternational Journal of Health Sciences and Research ISSN:
International Journal of Health Sciences and Research www.ijhsr.org ISSN: 2249-9571 Original Research Article Osteoporosis- Do We Need to Think Beyond Bone Mineral Density? Dr Preeti Soni 1, Dr Shipra
More informationMild morphometric vertebral fractures predict vertebral fractures but not non-vertebral fractures
DOI 10.1007/s00198-013-2460-0 ORIGINAL ARTICLE Mild morphometric vertebral fractures predict vertebral fractures but not non-vertebral fractures H. Johansson & A. Odén & E. V. McCloskey & J. A. Kanis Received:
More informationPostmenopausal osteoporosis is a systemic
OSTEOPOROSIS: HARD FACTS ABOUT BONES Steven T. Harris, MD, FACP* ABSTRACT As a consequence of the aging process, osteoporosis affects all men and women. Agerelated loss of bone mass leads to skeletal fragility
More informationOsteoporosis Diagnosis and Screening
Osteoporosis Diagnosis and Screening ANDREA,MD Associate Professor of Medicine and Obstetrics and Gynecology Georgetown University Hospital Washington, DC Osteoporosis and osteoporotic fracture are major
More informationPROCTER & GAMBLE and SANOFI-AVENTIS v ROCHE and GLAXOSMITHKLINE
CASES AUTH/1803/2/06 and AUTH/1804/2/06 PROCTER & GAMBLE and SANOFI-AVENTIS v ROCHE and GLAXOSMITHKLINE Bonviva Once Monthly slide kits Procter & Gamble and Sanofi-Aventis complained jointly about two
More informationAlendronate sodium in the management of osteoporosis
REVIEW Alendronate sodium in the management of osteoporosis P J J Prinsloo 1 D J Hosking 2 1 Dept of Clinical Chemistry, City Hospital, Nottingham, UK; 2 Dept Endocrinology and Diabetes, City Hospital,
More informationOsteoporosis. Current Trend in Osteoporosis Management for Elderly in HK- Medical Perspective. Old Definition of Osteoporosis
Current Trend in Osteoporosis Management for Elderly in HK- Medical Perspective Dr Dicky T.K. Choy Physician Jockey Club Centre for Osteoporosis Care and Control, CUHK Osteoporosis Global public health
More informationLong-term Osteoporosis Therapy What To Do After 5 Years?
Long-term Osteoporosis Therapy What To Do After 5 Years? Developing a Long-term Management Plan North American Menopause Society Philadelphia, PA October 11, 2017 Michael R. McClung, MD, FACP Institute
More informationOsteoporosis in Men. CME Away India & Sri Lanka March 23 - April 7, 2018
Osteoporosis in Men CME Away India & Sri Lanka March 23 - April 7, 2018 Richard A. Bebb MD, ABIM, FRCPC Consultant Endocrinologist Medical Subspecialty Institute Cleveland Clinic Abu Dhabi Copyright 2017
More informationWhite Rose Research Online URL for this paper: Version: Supplemental Material
This is a repository copy of Clinical effectiveness of bisphosphonates for the prevention of fragility fractures: A systematic review and network meta-analysis. White Rose Research Online URL for this
More informationNEW DEVELOPMENTS IN OSTEOPOROSIS: SCREENING, PREVENTION AND TREATMENT
NEW DEVELOPMENTS IN OSTEOPOROSIS: SCREENING, PREVENTION AND TREATMENT Judith Walsh, MD, MPH Departments of Medicine and Epidemiology and Biostatistics UCSF OSTEOPOROSIS: OVERVIEW Definitions Risk factors
More informationAETNA BETTER HEALTH Prior Authorization guideline for Injectable Osteoporosis Agents
AETNA BETTER HEALTH Prior Authorization guideline for Injectable Osteoporosis Agents Injectable Osteoporosis Agents Forteo (teriparatide); zoledronic acid Prolia (denosumab)] Authorization guidelines For
More informationASJ. How Many High Risk Korean Patients with Osteopenia Could Overlook Treatment Eligibility? Asian Spine Journal. Introduction
Asian Spine Journal Asian Spine Clinical Journal Study Asian Spine J 2014;8(6):729-734 High http://dx.doi.org/10.4184/asj.2014.8.6.729 risk patients with osteopenia How Many High Risk Korean Patients with
More informationOutline. Switching treatment. Evidence from randomized trials. The effects of switching 7/8/2016. When and for whom? Steven Cummings, MD
Outline Switching treatment When and for whom? Steven Cummings, MD Focus on switching from alendronate or risedronate Evidence about the effects of switching on BMD Purposes of switching Symptoms Poor
More information